Welcome coffee and networking

Anita Varma, Intellectual Property Partner, White & Case

Charles Larsen, Intellectual Property Partner, White & Case

 

Global Patent Enforceability: Status and Outlook​

Moderator:
Arlene Chow, Partner, Hogan Lovells

Panellists:
James Harrington, Chief Intellectual Property Counsel and Senior Vice President, Shire Pharmaceuticals
Konstantinos Andrikopoulos, Senior Director, IP, Vertex Pharmaceuticals
Philip Strassburger, Senior Vice President, Intellectual Property Strategy & Litigation, Purdue Pharma 
Shahan Islam, Senior Corporate Counsel, IP Enforcement Group, Pfizer Inc

The Role of Equivalents

• Developments in the UK – the implications of Actavis v Eli Lilly
• Elsewhere in Europe, are equivalents considered?
• What does this mean for life sciences companies in terms of patent protection and freedom to operate?

Zoe Butler, Partner, Powell Gilbert

Gunars Gaikis, Partner. Smart & Biggar

Recent Developments in Pharma Patent Case Law in Japan

Takanori Abe, Managing Partner, Abe & Partners

Duane C. Marks, Patent Counsel, Bio-Products, Eli Lilly and Company

• Why do the differences between biosimilars and generics matter?
• Do biologics necessitate date exclusivity protection?
• How do we Ensure Effective Protection for Antibodies?

Addressing Second Medical Use Infringement

 

Martina Tyreus Hufnal, Partner, Fish & Richardson

Lunch and Networking in the Hamilton Room

Taking part in these discussions offers delegates and speakers the opportunity to focus on topics of specific interest, within a small group. 35 minutes is set aside for each rotation – and delegates may choose two discussion tables. The roundtable discussion groups give delegates even more opportunity to share knowledge and opinion, and ends with a moderator round-up of key findings, providing delegates with an insight into all eight topics.

 

SESSION 1 - PLEASE CHOOSE YOUR FIRST TABLE FROM THE FOLLOWING:

Strategies in Second Medical Use Cases

Lydia McNally, VP, Oncology and US Patent Site, Novartis

Life Sciences Patents Open Table: Solving in-house counsel challenges  

Sally Shorthose, Partner, Bird & Bird

How do we Ensure Effective Protection of Antibodies?

Eldora Ellison, Director, Biotech/Chemical and Litigation Practice Groups, Sterne, Kessler, Goldstein & Fox
Bonnie Nannenga-Combs, Director, Sterne, Kessler, Goldstein & Fox

Considerations When Drafting CRISPR Patent Applications

Catherine Coombes, Patent Director, HGF

Licensing and joint ownership of IP: Who has Control?

Brion Berman, Senior Licensing Associate, Office of Research and Commercialisation, University of Central Florida

Pitfalls in Claim Drafting From a Litigator’s Perspective 

Brian Slater, Partner, Kramer Levin

Venue in Hatch-Waxman Cases after T.C. Heartland

Brendan O’Malley, Partner, Fitzpatrick, Cella, Harper & Scinto

Impact of IPR and PGR proceedings on Biologics and Biosimilars

Jennifer Fox, Partner, Brinks Gilson & Lione

Compulsory Licensing and Protecting Patented Drugs in India

Sunita Sreedharan, Founder & CEO, SKS Law

Pitfalls in Claim Drafting From a Litigator’s Perspective 

Brian Slater, Partner, Kramer Levin

Strategies in Second Medical Use Cases

Lydia McNally, VP, Oncology and US Patent Site, Novartis

How do we Ensure Effective Protection of Antibodies?

Eldora Ellison, Director, Biotech/Chemical and Litigation Practice Groups, Sterne, Kessler, Goldstein & Fox
Bonnie Nannenga-Combs, Director, Sterne, Kessler, Goldstein & Fox

Licensing and joint ownership of IP: Who has Control?

Brion Berman, Senior Licensing Associate, Office of Research and Commercialisation  University of Central Florida 

Venue in Hatch-Waxman Cases after T.C. Heartland

Brendan O’Malley, Partner, Fitzpatrick, Cella, Harper & Scinto

Compulsory Licensing and Protecting Patented Drugs in India

Sunita Sreedharan, Founder & CEO, SKS Law

Discussion group round-up: Key findings and points of note

Afternoon Tea and Networking in the Hamilton Room

IP Portfolio Management and Licensing Strategies: In-house Counsel Day-to-Day Challenges in Securing and Protecting Patents 

Moderator:
Andrea Reid, Partner, Dechert

Panellists:
Scott Alban, Vice President, Global Intellectual Property, AstraZeneca
Natasha Jones, Commercialisation Manager, University of Kentucky
Jeffrey Kopacz, Senior Director, Senior Patent Counsel, Alnylam Pharmaceuticals
Laural Boone, Senior Director & Patent Counsel, Alexion Pharmaceuticals
Tom McLean, Intellectual Property Counsel, Nimbus Therapeutics